BAT 8008
Alternative Names: BAT-8008Latest Information Update: 31 May 2024
At a glance
- Originator Bio-Thera Solutions
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 12 Apr 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in China (IV) (NCT06341114)
- 02 Apr 2024 Bio-Thera Solutions plans a phase I/II trial for Solid tumours (Late stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) (IV, Injection) (NCT06341114)
- 21 Mar 2023 Phase-I clinical trials in Solid tumours (Late stage disease, Metastatic disease) in China (IV) (NCT05620017)